Brinker Capital Investments, LLC Mirati Therapeutics, Inc. Transaction History

Brinker Capital Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jul 31, 2025	SELL	$41.99 - $62.38 $1.23 Million - $1.83 Million	-29,261 Closed	0 $0
Q3 2023 Jul 31, 2025	BUY	$27.8 - $45.35 $193,043 - $314,910	6,944 Added 31.12%	29,261 $1.27 Million
Q2 2023 Jul 31, 2025	SELL	$36.13 - $49.49 $26,338 - $36,078	-729 Reduced 3.16%	22,317 $806,000
Q1 2023 Jul 31, 2025	BUY	$36.54 - $54.26 $13,117 - $19,479	359 Added 1.58%	23,046 $856,000
Q4 2022 Feb 06, 2023	BUY	$41.27 - $98.62 $244,524 - $584,323	5,925 Added 35.35%	22,687 $1.03 Million
Q3 2022 Nov 01, 2022	BUY	$59.5 - $86.7 $160,174 - $233,396	2,692 Added 19.13%	16,762 $1.17 Million
Q2 2022 Jul 18, 2022	BUY	$39.16 - $88.71 $269,499 - $610,502	6,882 Added 95.74%	14,070 $945,000
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $544,994 - $1.09 Million	7,188 New	7,188 $591,000

3.52M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Brinker Capital Investments, LLC with notifications on news.